"Understanding the genes involved in OCD opens the door to precision therapies"
Dr. María del Pino Alonso envisions a near future in which it will be possible to develop much more effective precision drugs and therapies to treat obsessive-compulsive disorder (OCD). To move in that direction, she explains, it is essential to deepen our understanding of a disorder that affects one in every hundred people and that, in many cases, can become very serious and debilitating.
The path toward new treatments has been accelerated thanks to the largest genetic study to date on OCD, an international project that has brought together more than 53,000 affected individuals and 200 researchers from around the world over more than twenty years. This work has identified 25 genes linked to the development of the disorder, distributed across 30 specific regions of the genome. This finding opens the door to innovative therapeutic approaches and offers hope to those living with this disorder and their families.
Dr. Alonso has led the participation of Bellvitge University Hospital in this pioneering research. We spoke with her not only about this scientific breakthrough, but also about key issues such as early detection, risk factors, the needs of those affected, and the stigma that still surrounds them.